Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker-Symbol: B6E
Tradegate
05.06.25 | 21:40
28,100 Euro
+0,14 % +0,040
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
28,04028,30013:32
28,04028,30013:29
PR Newswire
222 Leser
Artikel bewerten:
(1)

Swedish Orphan Biovitrum AB: Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025

STOCKHOLM, June 4, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will have a strong scientific presence at this year's ERA congress in Vienna (4-7 June) with a total of eight presentations: six oral presentations and two posters. We are proud that two of our abstracts have been recognised in the top 10 abstracts at ERA 2025, as selected by expert reviewers coordinated by the ERA Paper Selection Committee.

Notably, 52-week results from the open-label-period (OLP) of the VALIANT Phase 3 study will be presented for the first time. This data will be featured in an oral presentation by Professor Fadi Fakhouri (Lausanne University Hospital and University of Lausanne) during the session "Innovative Kidney Trials", on 6 June 2025 at 15:00 CEST.

The two abstracts selected in the top 10 at the conference both highlight important subgroup results from the randomised-controlled-period (RCP) of the VALIANT Phase 3 study covering the treatment effect of pegcetacoplan at 26 weeks in patients with nephrotic range proteinuria at baseline, and the effect of pegcetacoplan in adolescents at 26 weeks.

Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi says, "The large number of oral presentations, including one achieving the highest ranking of all ERA abstracts and a second in the top 10, reflects the importance of the data and research outputs being generated from our work aimed at advancing treatments for rare kidney conditions."

Key data to be presented at ERA 2025

VALIANT

A thematic analysis of healthcare provider

perspective on the care pathway and unmet
needs in patients with C3 glomerulopathy
(C3G) and primary immune complex
membranoproliferative

glomerulonephritis (IC-MPGN) in the US and Europe.

Presenter: Carly Rich

Poster presentation

Session: Glomerular & tubulo-interstitial diseases

Room: XWall 1 Mozart Symphony No. 40

Date: 5 June 2025

Time: 13:12 CEST

Pegcetacoplan treatment effect in patients with

nephrotic range proteinuria: results from the

VALIANT Phase 3 study in patients with C3G or

Primary (Idiopathic) IC-MPGN

Presenter: Antonio Mastrangelo

Oral presentation

Session: FC 14: About C3 and IgA Glomerulonephritis

Room: Hall F1

Date: 6 June 2025

Time: 08:15 CEST

Targeted treatment with pegcetacoplan for

adolescents with C3G or Primary (Idiopathic) IC-

MPGN in the VALIANT Phase 3 trial

Presenter: Antonio Mastrangelo

Oral presentation

Session: FC 14: About C3 and IgA Glomerulonephritis

Room: Hall F1

Date: 6 June 2025

Time: 08:30 CEST

Pegcetacoplan demonstrates clinically significant

responses in C3G and Primary (Idiopathic)
IC-MPGN patients with or without concomitant

immunosuppression in VALIANT

Presenter: David Kavanagh

Oral presentation

Session: FC 14: About C3 and IgA Glomerulonephritis

Room: Hall F1

Date: 6 June 2025

Time: 09:30 CEST

Association between proteinuria and clinically

meaningful endpoints in patients with C3G / IC-

MPGN: a Delphi consensus of European experts

Presenter: Fernando Caravaca-Fontán

Poster Presentation

Session: Chronic Kidney Disease

Room: Strauss Wiener Blut

Date: 6 June 2025

Time: 13:06 CEST

Pegcetacoplan for C3G and primary (idiopathic) IC-

MPGN: 52-week results from the phase 3 VALIANT

trial show sustained efficacy

Presenter: Fadi Fakhouri

Oral presentation

Session: Innovative Kidney Trials

Room: The Square

Date: 6 June 2025

Time: 15:00 CEST

Targeted Treatment with Pegcetacoplan for post-

Transplant Recurrent C3G or Primary (idiopathic)
IC-MPGN in the VALIANT Phase 3 Trial

Presenter: Michiel Oosterveld

Focused Oral presentation

Session: Glomerular & tubulo-interstitial diseases

Room: Focused Oral Room 3

Date: 6 June 2025

Time: 15:54 CEST

Pegcetacoplan Treatment appears to halt disease

progression in C3G and Primary (Idiopathic)
IC-MPGN patients: results from the Phase 3 VALIANT study

Presenter: Daniel Gale

Focused Oral presentation

Session: Glomerular & tubulo-interstitial diseases

Room: Focused Oral Room 3

Date: 6 June 2025

Time: 16:06 CEST

About the VALIANT Study

The VALIANT Phase 3 study (NCT05067127) was a randomised, placebo-controlled, double-blinded, multi-centre study evaluating pegcetacoplan efficacy and safety in 124 patients who were 12 years of age and older, with C3G or primary IC-MPGN. It is the largest single trial conducted in these populations and the only study to include adolescent and adult patients, with native and post-transplant kidneys. During the 26-week randomised-controlled-period (RCP) of VALIANT, patients received twice weekly subcutaneous pegcetacoplan or placebo. The RCP was followed by a 26-week open-label period (OLP) in which all patients received pegcetacoplan. The primary endpoint of the study was the log transformed ratio of urine protein-to-creatinine ratio (UPCR) at week 26 compared to baseline.

About Sobi

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn, BlueSkyX

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-showcases-breadth-of-data-in-c3g-primary-ic-mpgn-at-era-2025,c4158688

The following files are available for download:

https://mb.cision.com/Main/14266/4158688/3485482.pdf

Sobi Showcases Breadth of data at ERA 2025

Cision View original content:https://www.prnewswire.co.uk/news-releases/sobi-showcases-breadth-of-data-in-c3gprimary-ic-mpgn-at-era-2025-302472985.html

© 2025 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.